The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 4 May 2026•Updated 5 May 2026•

1 min read

BioMarin Pharmaceutical Q1 Earnings Miss Estimates Amid Year-Over-Year Decline

Key Facts

1BioMarin Pharmaceutical reported quarterly earnings of $0.76 per share, missing the consensus estimate of $0.94 per share.

2The company's earnings declined compared to the previous year's quarter, which saw earnings of $1.13 per share.

29 days ago

Version History

1 additional source confirmed this story

Version 229 days ago

What changed: Added Q1 earnings results for LeMaitre Vascular and Pitney Bowes, showing an earnings beat and an in-line performance respectively.

Version 129 days ago

What changed: Updated the story to include the revenue beat, the upward revision of 2026 guidance following the Amicus deal, and identified higher costs as the driver behind the earnings miss.

BioMarin Pharmaceutical reported first-quarter earnings of $0.76 per share, missing the consensus analyst estimate of $0.94 per share. Despite the earnings miss and a year-over-year decline, the company’s quarterly sales exceeded expectations due to a robust revenue beat. In related market news, LeMaitre Vascular (LMAT) achieved earnings of $0.68 per share, surpassing analyst expectations of $0.66. Meanwhile, Pitney Bowes (PBI) matched earnings estimates exactly at $0.47 per share. These updates provide a broader view of the current earnings season, contrasting BioMarin's immediate cost pressures with the outperformance of LMAT. Investors are now weighing the impact of rising expenses against the strengthening revenue trajectories across these sectors.